BeiGene’s Liang joins Tessera as president, CFO; plus Vera, Entasis, Iterion and Anticancer
Howard Liang joined gene writing company Tessera Therapeutics Inc. as president and CFO. Liang was most recently CFO and chief strategy officer at BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160), leading the company’s listings on NASDAQ and the Hong Kong stock exchange. Tessera also hired Madhusudan Peshwa as CTO for cell therapy; Bill Querbes as SVP of therapeutics discovery and translational sciences; Cecilia Cotta-Ramusino as SVP, platform development, Vikram Ranada as SVP, corporate development; David Pollard as head of bioprocess; and Steve Garbacz as head of finance.
Sean Grant joined immunology company Vera Therapeutics Inc. (NASDAQ:VERA) as CFO. Grant was most recently VP of corporate strategy and business development at CareDx, and previously VP of healthcare investment banking at Citigroup...